Dyslipidemia In Type 2 Diabetes Mellitus Patients Research Articles

Biochemical association of regulatory variant of KLF14 genotype in the pathogenesis of cardiodiabetic patients.

The study focuses on examining the relationship between a single nucleotide polymorphism (SNP) in KLF14 rs4731702 and risk of type 2 diabetes mellitus (T2DM) and dyslipidemia in different ethnic populations. The purpose of this study was to evaluate the association between KLF14 rs4731702 and serum lipid profile and to determine the frequency distribution of KLF14 rs4731702 among T2DM and cardiometabolic patients. A total of 300 volunteers were recruited, consisting of three groups: 100 healthy individuals, 100 individuals diagnosed with T2DM, and 100 individuals diagnosed with cardiometabolic disorders. Biochemical analysis of blood samples was conducted to assess various biomarkers related to glycemic control and lipid profile. This involved measuring levels of glucose, triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and ApoA1. Genotyping analysis was performed to investigate KLF14 rs4731702 polymorphism. The Tetra ARMS-PCR method was employed for genotyping analysis. The results of biochemical profiling revealed a significant association between altered glycemic biomarkers and lipid profile in diseased patients compared to healthy participants. The frequencies of KLF14 rs4731702 alleles and genotypes were compared between the control group and T2DM group. A statistically significant difference was observed, indicating a potential association between KLF14 rs4731702 and T2DM. In the dominant inheritance model of KLF14 rs4731702 SNP, a statistically significant difference [odds ratio (95% confidence interval)] of 0.56 (0.34 -0.96) was found between the control and T2DM subjects. This suggests that the presence of certain genotypes influences the risk of T2DM. In T2DM patients, individuals carrying the C allele exhibited compromised insulin sensitivity, decreased HDL-C and ApoA1 levels, and increased serum glucose, TG, and LDL-C concentrations. Conversely, TT genotype carriers demonstrated increased levels of HDL-C and ApoA1, lower insulin resistance, serum glucose, LDL-C, and TG levels. The study's findings indicate that dyslipidemia in T2DM patients is associated with reduced KLF14 functionality due to CC and CT genotypes, leading to insulin resistance and an increased risk of cardiovascular diseases. Additionally, risk of KLF14 rs4731702 polymorphism was found to increase with age and was more prevalent in female than in male individuals. These insights contribute to understanding genetic factors influencing the development and progression of T2DM and dyslipidemia in different ethnic populations.

Serum Omentin-1 Levels in Patients with Type 2 Diabetes Mellitus and their Correlation with Lipid Profile: A Case-control Study

Introduction: Type 2 Diabetes Mellitus (T2DM) is characterised by a variable degree of insulin resistance, leading to hyperglycemia. Serum omentin-1, an important adipocytokine, plays a role in maintaining tissue sensitivity to insulin and lipid metabolism. Therefore, circulating omentin-1 can serve as a biomarker for obesity, diabetes, and dyslipidemia. Aim: The aim of this study was to compare serum omentin-1 levels between type 2 diabetic cases and non diabetic controls, and to investigate the correlation of omentin-1 levels with the lipid profile. Materials and Methods: A hospital-based case-control study was conducted at Government Medical College, Trivandrum, from December 2017 to November 2018. The study included 30 T2DM patients and 30 non diabetic controls. Serum omentin-1 levels, fasting blood sugar, glycated haemoglobin (HbA1C), and serum lipid profile were measured in all study subjects. Statistical analysis included Student’s t-test and Pearson’s correlation coefficient to assess the correlation between variables. Chi-square test was performed to analyse age and sex distribution among the study groups. Results: The mean age of diabetic cases was 56.7±7.9 years, while the mean age of non diabetic controls was 52.9±5.5 years. Among the subjects, 43% of diabetics and 50% of non diabetics were male, while 57% of diabetics and 50% of non diabetics were female. The mean value of serum omentin-1 levels was significantly lower in the diabetic population (273.37±60.18 ng/mL) compared to the non diabetic controls (573.4±51.6 ng/mL) with a p-value of <0.001. Serum omentin-1 showed a significantly strong negative correlation with total cholesterol, low-density lipoproteins (LDL), and triglycerides, and a positive correlation with high-density lipoproteins (HDL). Conclusion: In the present study, serum omentin-1 levels were significantly lower in the diabetic population, and their lipid profile exhibited abnormal values. This suggests that omentin promotes insulin sensitivity and affects lipid metabolism, thus preventing insulin resistance and dyslipidemia in T2DM patients. Therefore, omentin may play a role in reducing cardiovascular complications.

Elevated IL-31 and IL-31RA with dyslipidemia in T2DM patients

Type 2 Diabetes mellitus (T2DM) is characterized by elevated of blood glucose, and considered as a chronic metabolic disease. Uncontrolled blood glucose levels cause many dangerous complications. One of these complications are diabetic foot ulcers (DFU). About 15% of these patients suffering of DFU that affected on their lives. Approximately 8.5% Iraqi suffer from T2DM. Sixty T2DM patients (32 male and 28 female) aged 39-65 years that participated in the present study. Thirty apparently healthy subjects (12 male and 18 female) were classified as a control group. Age and BMI are not significantly different between patients and controls. This was made to exclude the influence of body mass and age on the results. There is an expected significant increase in fasting blood glucose (FBG) (p <0.001) and glycated hemoglobin (HbA1c). The results showed a significant increase (p<0.001) in serum triglyceride (TG), VLDLc in T2DM as comparison with the control group, while There were no significant differences among T2DM patients and control group in total cholesterol (TC), HDLc and LDLc. This result maybe was by the effect of diabetic drug on lipid profile where some drugs such as metformin that reducing cholesterol.

The Effects of Obesity and Physical Activity on Dyslipidemia in Persons With Type 2 Diabetes

OBJECTIVES This study was conducted to examine the effect of obesity, and physical activity on the prevalence of dyslipidemia in persons with type 2 diabetes mellitus (T2DM).METHODS A cross-sectional , correlational design was used. Participants aged 20 years or older were recruited from a diabetes clinic affiliated with a university hospital. Body composition, blood glucose, glycated hemoglobin, and blood lipid level were measured in addition to self-reported physical activity. Final data analysis was conducted with 177 participants. The differences on physical activity measures and body composition between those with or without dyslipidemia were analyzed using independent t-tests. The associations between dyslipidemia and physical activity and obesity were assessed with the odds Ratio (OR) and 95% confidence intervals (CI) after adjusting potential confounding factors.RESULTS The participation rate of regular physical activity in T2DM patients was 55.9%. BMI and regular physical activity participation influenced the prevalence of dyslipidemia in persons with T2DM. The regular physical activity participation rate of T2DM patients without dyslipidemia was higher than that of T2DM patients with dyslipidemia (p<.05). Moreover, participation in regular physical activity decreased the risk of dyslipidemia prevalence (p<.05). With regard to body composition, T2DM patients with dyslipidemia had a higher body mass index (p<.01). As the body mass index 1 increased, odd ratio of the dyslipidemia prevalence increased 1.21 times (p<.05).CONCLUSIONS The risk of dyslipidemia in T2DM patients was influenced by BMI and participation in regular physical activity. Therefore, reducing obesity through regular physical activity will be a way to lower the prevalence of dyslipidemia in T2DM.

Relationship between Atherogenic Index of Plasma with HbA1c Levels in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus (T2DM) is a global health problem due to an increasing prevalence and incidence. HbA1c as aparameter for glycemic control is still above the desired target of 7%. Atherogenic Index of Plasma (AIP) is predicted to be anindicator of cardiovascular disease risk in T2DM. Dyslipidemia in T2DM patients showed a result of increased triglycerideand decreased HDL cholesterol levels. This study aimed to determine the relationship between HbA1c and AIP, triglycerides,and HDL cholesterol in T2DM patients. An analytical observational study using a cross-sectional method on 74 DMT2patients who underwent HbA1c and lipid profile examinations in January-March 2020. Atherogenic index of plasma wascalculated by the logarithmic equation (triglycerides/HDL cholesterol). Data were analyzed by SPSS 25.0. The relationshipbetween HbA1c with AIP, triglycerides, and HDL cholesterol using the Pearson correlation test. Atherogenic index of plasma(0.25±0.25) and triglycerides (211.92±146.09 mg/dL) were found to be higher in the poor glycemic control group (HbA1c> 7%) than AIP (-0.04±0.20) and triglycerides (108.96±38.96 mg/dL) in the good glycemic control group (p < 0.05). HDLcholesterol (40.08±12.64 mg/dL) was found to be higher in the poor glycemic control group than HDL cholesterol(52.28±18.12 mg/dL) in the good glycemic control group (p < 0.05). There was a significant positive correlation betweenHbA1c and AIP (r=0.411, p=0.000), HbA1c with triglycerides (r=0.418, p=0.000), and a significant negative correlationbetween HbA1c and HDL cholesterol (r=-0.233, p=0.046). Insulin resistance can cause lipid metabolism disorders,inflammation, oxidative stress, and coagulation disorders. Maintaining glycemic control and lipid control plays an importantrole in preventing diabetes complications. There is a significant positive correlation between HbA1c and AIP, HbA1c andtriglycerides, and a significant negative correlation between HbA1c and total cholesterol in T2DM patients.

Prevalence of Dyslipidaemia among Type 2 Diabetes Mellitus Patients in the Western Cape, South Africa.

Dyslipidaemia, an irregular aggregate of lipids in the blood is common in diabetes and cardiovascular disease sufferers. A cross-sectional study on the prevalence of dyslipidaemia was performed among type 2 diabetes mellitus (T2DM) patients in the Western Cape, South Africa. Patients (n = 100) that participated in the study were within the age range of 19–68 years, of whom 89% were observed to have serum lipid abnormalities. Out of the 100 patients, 56%, 64%, 61%, and 65% were recorded to have high total cholesterol (TC), hypertriglycemia, increased low-density lipoproteins cholesterol (LDL-C), and reduced high-density lipoproteins cholesterol (HDL-C), respectively. In male diabetic patients, a marked prevalence of (94%) dyslipidemia was noted, of which 52% were affected by high TC (5.3–7.9 mmol/L), with 70% having a high level of triglyceride (TG) [1.72–7.34 mmol/L], while 60% had a high LDL-C (3.1–5.5 mmol/L), including 78% with low HDL-C (0.7–1.1 mmol/L). In comparison, 84% of diabetic females had dyslipidemia, with high TC (5.1–8.1 mmol/L), hypertriglycemia (1.73–8.63 mmol/L), high LDL-C (3.1–5.6 mmol/L), and low levels of HDL-C (0.8–1.1 mmol/L) affecting 60%, 58%, 62%, and 52% of the patients, respectively. This study showed the importance of screening and the regular surveillance of dyslipidaemia in T2DM patients as there is a paucity of data on it in Africa.

Effects of Probiotic Supplementation on Dyslipidemia in Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

The effectiveness of probiotic consumption in controlling dyslipidemia in type 2 diabetes mellitus (T2DM) has been unclear. We reviewed relevant randomized controlled trials (RCTs) to clarify the effect of probiotic intake on dyslipidemia in T2DM patients. The Web of Science, Scopus, PubMed and Cochrane Library databases were used for searching relevant RCTs published up to October 2020. The total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) concentrations were selected as the primary indicators for dyslipidemia. The results of 13 eligible RCTs showed that probiotic intake could significantly reduce TC (SMD: −0.23, 95% CI: (−0.37, −0.10)) and TG (SMD: −0.27, 95% CI: (−0.44, −0.11)) levels, but did not regulate LDL-C or HDL-C concentrations. Subgroup analysis showed that multispecies probiotics (≥two species), but not single-species probiotics, significantly decreased TC and TG concentrations. Furthermore, powder, but not liquid, probiotics could reduce TC and TG concentrations. This meta-analysis demonstrated that probiotic supplementation is helpful in reducing TC and TG concentrations in T2DM patients. However, more well-controlled trials are needed to clarify the benefits of probiotics on dyslipidemia in T2DM patients.

DISTRIBUTION PATTERNS AND RISK FACTORS OF DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL STUDY IN BOGOR, INDONESIA

Objective: Type 2 diabetes mellitus (T2DM) patients tend to have abnormal lipid profiles, explaining the association between elevated cholesterol andtriglyceride levels in diabetic patients and coronary heart disease. This study aims to evaluate how the common risk factors for dyslipidemia affectthe lipid profile of diabetic patients and to determine which factors can be used as predictors for the occurrence of dyslipidemia in T2DM patients.Methods: A total of 238 diabetic patients (63 male and 175 female; age: 31–70 years) were enrolled in this cross-sectional study. All of them hadundergone regular examinations in cohort studies on risk factors for non-communicable diseases conducted by the Ministry of Health in Bogorbetween December 2017 and January 2018.Results: The result found that age differences did not affect lipid profile levels, and the females had higher mean values of body mass index (p<0.001),total cholesterol (TC) (p<0.05), and high-density lipoprotein (HDL) (p<0.001) than the males. The most common occurrences of dyslipidemia werehigh TC level (57.1%), followed by high low-density lipoprotein (LDL) level (47.1%), high triglyceride level (37.4%), and low HDL level (16.4%). Beingoverweight was found to be the best predictor of dyslipidemia.Conclusion: The results of this study suggest that in T2DM patients, sex affects TC and HDL levels, whereas age does not exert a significant effect onthe lipid profiles. In addition, poor glycemic control, hypertension, and obesity may serve as predictors of dyslipidemia in T2DM patients.

Effect of 25-hydroxyvitaminD on Helicobacter pylori eradication in patients with type2 diabetes.

SummaryBackgroundVarious studies have reported a lower Helicobacter pylori eradication rate and a more frequent reinfection rate in type 2 diabetes mellitus (T2DM). Vitamin D has anti-inflammatory and immunoregulatory activity and the role of the vitamin D receptor (VDR) in the antimicrobial activity against H. pylori has been reported. When it comes to the risk factors of H. pylori eradication, the function of vitamin D is not always taken into account. The aim of this study was to assess the role of 25-hydroxyvitamin D in H. pylori eradication in T2DM.MethodsIn this retrospective study data from 160 patients with T2DM who underwent eradication therapy for H. pylori in Anhui Provincial Hospital between July 2015 and September 2017 were analyzed. According to eradication status, patients were divided into two groups, the successful eradication group (n = 124) and the eradication failure group (n = 36). The following information was obtained from participants’ records before eradication treatment: age, sex, body mass index (BMI), duration of T2DM, prescription of medication use, smoking and drinking history. All patients were tested for glycated hemoglobin (HbA1c), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL‑C), triglyceride (TG) and 25-hydroxyvitamin D (25-OHD) at baseline.ResultsThe H. pylori was eradicated in 124 (77.5%) patients, while in 36 (22.5%) patients the treatment was unsuccessful. The eradication failure group had a lower mean vitamin D concentration than the group with successful eradication (15.09 ± 7.72 ng/ml vs. 19.87 ± 6.35 ng/ml, p = 0.004). The estimated odds ratio (OR) for eradication failure in individuals with serum vitamin D deficiency (<20 ng/ml) compared to those with sufficient vitamin D levels (>30 ng/ml) were 1.489 (95% confidence interval, CI: 1.046–2.121, P = 0.027), Individuals with long duration of diabetes (≥10 years) had odds of eradication failure of 1.467 (95% CI: 1.017–2.114, P = 0.040) compared to subjects with short duration of diabetes (<10 years).ConclusionsLower 25-OHD was not only associated with H. pylori eradication failure but was also related to dyslipidemia in T2DM patients. Increasing serum 25-OHD to appropriate levels by activated vitamin D use may improve the eradication rate.

Dyslipidaemia as a risk factor for erectile dysfunction in type 2 diabetes mellitus patients

BackgroundDespite epidemiological studies worldwide have documented erectile dysfunction (ED) as a major complication of type 2 diabetes Mellitus (T2DM) in men, only limited research reported on determinants of ED in this population. The study aimed at examining the association of ED with dyslipidaemia in T2DM patients. MethodsThe study enrolled 813 consecutive eligible adult male T2DM patients attending the endocrinology departments of a tertiary teaching hospital in Bangladesh. Sexual function was assessed using modified International Index of Erectile Function (IIEF) in face-to-face interview and collected along with sociodemographic information. Diabetes and lipid profile and treatment history were collected from patient's treatment records. Association of ED with dyslipidaemia was assessed using multivariable logistic regression adjusting for potential confounders. ResultPrevalence of ED among the T2DM patients was very high (72.7%), of which around half had moderated-to-severe ED. Odds of having dyslipidaemia among T2DM patients with ED is 2.3 times higher than those without. The odds increased by approximately 3 fold for an abnormal High Density Lipoprotein level and by 2.7 fold for abnormal Low Density Lipoprotein. ConclusionDyslipidaemia was associated with increased ED risk among T2DM. Abnormal lipoprotein level particularly were found to pose greater risk.

The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings

Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. A multicentre, non-interventional survey conducted in 6 Middle Eastern countries (Bahrain, Oman, Qatar, United Arab Emirates, Kingdom of Saudi Arabia and Kuwait). Patients with T2DM (n = 3338) taking LLD treatment for ≥3 months with no dose change for ≥6 weeks were enrolled. The mean age (SD) of T2DM patients was 56.6 ±10.6 years; the majority (99%) were on statin monotherapy. Only 48% of these patients achieved their low density lipoprotein cholesterol (LDL-C) goal and 67.7% of the patients had a high cardiovascular disease (CVD) risk according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. Of those who achieved LDL-C goals (n=1589), approximately one-third were at very high CVD risk and the patients who had received statin monotherapy showed the highest proportion in LDL-C goal attainment, followed by those treated with fibrate monotherapy. In a multivariate logistic regression model, taking drugs daily (odds ratio, OR: 1.64, 95% CI 1.25, 2.15) and older age (OR: 1.09, 95% CI 1.01, 1.18) were significantly associated with better odds of attaining LDL-C target. In contrast, patients with higher levels of ApoA1 (OR: 0.73, 95% CI [0.67,0.79]), Metabolic Syndrome (OR: 0.64, 95% CI [0.53, 0.76]), higher CV risk (OR: 0.33, 95% CI 0.27, 0.41), those who forgot to take their medication (OR: 0.74, 95% CI 0.62,0.88) and those who stopped taking medication when cholesterol became normal (OR: 0.67, 95% CI 0.55,0.82) were significantly associated with lower odds of attaining LDL-C target. The results of this study highlight the suboptimal management of dyslipidaemia in T2DM patients at high and very high risk of CVD.

Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes.

The aim of this review is to describe in diabetic patients the determinants underlying atherogenic dyslipidemia, a complex dyslipidemia defined as the coexistence of fasting hypertriglyceridemia and low high-density lipoprotein cholesterol level. Atherogenic dyslipidemia is often comorbid with hyperglycemia in patients with the common form of type 2 diabetes mellitus (T2DM), namely that associated with obesity, insulin resistance, hyperinsulinemia and the metabolic syndrome phenotype. The role of triglyceride-rich lipoproteins, both fasting and nonfasting, is increasingly considered as a direct driver of atherosclerosis in diabetic patients, even in those receiving best standards of care, including low-density lipoprotein cholesterol level adequately controlled by statins and/or ezetimibe. The residual cardiovascular risk related to atherogenic dyslipidemia in T2DM patients can be inferred from subgroup analysis of diabetic patients within landmark lipid-lowering trials, or from T2DM-only trials, such as Fenofibrate Intervention and Event Lowering in Diabetes study or Action to Control Cardiovascular Risk in Diabetes-Lipid trial. The presence of atherogenic dyslipidemia markedly increases cardiovascular risk, and there is evidence that part of the residual cardiovascular risk in T2DM can be safely and effectively reduced by fibrates. Ongoing trials will determine whether new classes of drugs or dietary intervention targeting hypertriglyceridemia (such as n-3 fatty acids or SPPARMα) will reduce macro and microvascular residual risk in T2DM patients with atherogenic dyslipidemia at inclusion.

Albuminuria status and patterns of dyslipidemia among type 2 diabetes black patients managed at a tertiary health-care hospital: A Post hoc analysis.

Cardiovascular disease (CVD) risk in type 2 diabetes mellitus (T2DM) increases with the development of albuminuria and is related in part to dyslipidemia. The present analysis assessed lipid profile and patterns of dyslipidemia in T2DM patients according to albuminuria status. This was a post hoc analysis of data from 181 T2DM patients seen at a tertiary health-care hospital and enrolled in a cross-sectional study of albuminuria status. Abnormal albuminuria was defined as microalbuminuria [albumin to creatinine ratio (ACR) 30-299.9 mg/g] or macro-albuminuria (ACR ≥300 mg/g). Atherogenic dyslipidemia was defined as triglycerides (TGs) ≥150 mg/dL and/or high-density lipoprotein-cholesterol (HDL-c) <40 mg/dL in men and <50 mg/dL in women using international consensus criteria. High levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), HDL-c, non-HDL-c, TG, and low level of HDL-c were defined according to 2012 American Association of Clinical Endocrinologists' guidelines. Comparisons between T2DM patients with and without abnormal albuminuria were done using Chi-square test, Student's t-test, or two-sample t-test with equal variance and Mann-Whitney test as appropriate. P< 0.05 defined the level of statistical significance. Of the 181 T2DM patients, 93 (51%) had abnormal albuminuria with 32% and 19% having microalbuminuria and macro-albuminuria, respectively. Average TC, HDL-c, HDL-c, non-HDL-c, and TG levels were 171 ± 41, 111 ± 36, 38 ± 16, 133 ± 38, and 98 (45-234) mg/dL, respectively. These values were significantly lower for TC (P = 0.047), LDL-c (P = 0.030), and non-HDL-c (P = 0.05) in comparison with patients with normal albuminuria. Low HDL-c (64.5%) and high TG (9.7%) were, respectively, the most and less frequent patterns of isolated dyslipidemia in patients with abnormal albuminuria. Atherogenic dyslipidemia with mainly low HDL-c levels is common in T2DM patients with abnormal albuminuria and could contribute to CVD and renal disease progression.

LDLR C1725T Gene Polymorphism Frequency in Type 2 Diabetes Mellitus Patients With Dyslipidemia.

BackgroundDyslipidemia has a substantial role in the development of cardiovascular diseases in patients with type 2 diabetes mellitus (T2DM). Determining the genetic profile of T2DM patients with dyslipidemia is important in order to reduce the risk of microvascular and macrovascular complications. Low-density lipoprotein receptor (LDLR) plays a critical role in plasma lipoprotein hemostasis. LDLR mutations/polymorphisms cause changes at the lipoprotein level. The objective of this study is to determine the frequency of LDLR (rs179989) polymorphisms in Turkish T2DM patients with dyslipidemia.MethodsThe study group consisted of 217 T2DM patients with dyslipidemia including 28 cases with myocardial infarction and 212 healthy controls. Genomic DNA was isolated from venous blood samples and genotype analysis was carried out on the LightCycler® 480 instrument. The χ2 test was used to compare genotype distributions.ResultsThere were no significant differences in the frequency or allelic distribution of the LDLR C1725T (rs1799898) genotype between the type 2 diabetic dyslipidemia patients and the control group (P > 0.05).ConclusionLDLR C1725T polymorphism was not associated with lipid parameters, and dyslipidemia in T2DM patients.